The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

Official statistics published by the UK Health Security Agency highlight trends in sexually transmitted infection diagnoses in England. Information is available from the GUMCAD STI Surveillance System and the CTAD Chlamydia Surveillance System at the following links respectively:

https://www.gov.uk/guidance/gumcad-sti-surveillance-system

https://www.gov.uk/guidance/ctad-chlamydia-surveillance-system

Local authorities in England are responsible for commissioning comprehensive, open access sexual health services, including sexually transmitted infection (STI) services, through the Public Health Grant, which was funded at £3.884 billion in 2025/26. It is for individual local authorities to decide their spending priorities, based on an assessment of local need, and to commission the blend of services that best suits their population, including decisions about online, face to face, or postal testing services.

The UK Health Security Agency published the STI prioritisation framework in 2024, which enables local systems to identify the best suite of interventions for their local populations.

Bacterial sexually transmitted infections (STI) such as chlamydia and gonorrhoea are a recognised cause of pelvic inflammatory disease, which can in some cases lead to tubal factor infertility.

Chlamydia is the most commonly diagnosed STI. It often has no symptoms but, if left untreated, can have serious health complications in women, including pelvic inflammatory disease, ectopic pregnancy, and tubal factor infertility. It has been estimated that 0.5% of untreated chlamydia infections can lead to tubal factor infertility.

The National Chlamydia Screening Programme is a public health programme aimed at reducing the reproductive harm caused by untreated chlamydia infections. The programme involves making opportunistic offers of a chlamydia test to young women aged 15 to 24 years old without symptoms, with the primary aim of reducing the health harm caused by untreated chlamydia infection.

NHS England is supporting the Infected Blood Compensation Authority (IBCA) with their engagement with National Health Service organisations for the purposes of sharing data on patients who received a blood transfusion before 1996 and who have tested positive for HIV or hepatitis C, to support compensation claims.

This support includes highlighting the requirement to provide information promptly to the IBCA to support claims, conducting workshops to understand how the IBCA can most effectively gather information from NHS organisations, and drafting guidance for patients, clinicians, and information governance professionals so that NHS organisations feel confident about sharing information to support claims.

Dedicated local sexual health services play a key public health role in the diagnosis, early treatment, and management of sexually transmitted infections (STIs). Individual local authorities, funded through a ring-fenced Public Health Grant (PHG), are responsible for commissioning decisions about the sexual health services that best meet the needs of their local populations, including providing open-access sexual health testing and treatment services.

In 2025/26, we are increasing funding through the PHG to £3.858 billion, providing local authorities with an average 5.4% cash increase and a 3% real terms increase. This represents a significant turning point for local health services, marking the biggest real-terms increase after nearly a decade of reduced spending.

We continue to support the delivery of local sexual health services, including addressing rates of STIs, by providing guidance and data to support local decision makers. In October 2024, the UK Health Security Agency (UKHSA) published the STI Prioritisation Framework, which, combined with ongoing support from the UKHSA, will enable local systems to identify which combination of interventions to focus on for which populations, informed by the local situation.

The Department is also investing over £6 million to deliver a National HIV Prevention Programme between 2021 to 2026 to raise awareness of HIV, and STI testing and prevention strategies. Also, the Department, the UKHSA, NHS England, and a broad range of system partners are developing the new HIV Action Plan, which we aim to publish this year. A key objective of the plan will be to stabilise and support system enablers, including the wider sexual and reproductive health system.

Dedicated local sexual health services play a key public health role in the diagnosis, early treatment, and management of sexually transmitted infections (STIs). Individual local authorities, funded through a ring-fenced Public Health Grant (PHG), are responsible for commissioning decisions about the sexual health services that best meet the needs of their local populations, including providing open-access sexual health testing and treatment services.

In 2025/26, we are increasing funding through the PHG to £3.858 billion, providing local authorities with an average 5.4% cash increase and a 3% real terms increase. This represents a significant turning point for local health services, marking the biggest real-terms increase after nearly a decade of reduced spending.

We continue to support the delivery of local sexual health services, including addressing rates of STIs, by providing guidance and data to support local decision makers. In October 2024, the UK Health Security Agency (UKHSA) published the STI Prioritisation Framework, which, combined with ongoing support from the UKHSA, will enable local systems to identify which combination of interventions to focus on for which populations, informed by the local situation.

The Department is also investing over £6 million to deliver a National HIV Prevention Programme between 2021 to 2026 to raise awareness of HIV, and STI testing and prevention strategies. Also, the Department, the UKHSA, NHS England, and a broad range of system partners are developing the new HIV Action Plan, which we aim to publish this year. A key objective of the plan will be to stabilise and support system enablers, including the wider sexual and reproductive health system.

Scaling up HIV testing for all population groups will be a key objective of the new HIV Action Plan, which is due to be published in summer 2025. We are currently working together with the UK Health Security Agency, NHS England, and other key stakeholders and considering which testing interventions would be best suited to achieve our ambitions, including the most effective role for online testing.

On 28 November 2024, the Prime Minister confirmed £27 million of additional funding for 2025/26 to expand the highly successful National Health Service emergency department opt-out HIV testing programme, supporting national HIV testing. As part of the extension of the programme, approximately 90 sites will be offered funding to roll out HIV opt-out testing until March 2026. Further funding will be confirmed in due course after the spending review phase two process has concluded.

Local authorities in England are responsible for commissioning open access sexual health services, including HIV and sexually transmitted infection (STI) testing services, through the public health grant, funded at £3.6 billion in 2024/25. It is for individual local authorities to decide their spending priorities based on an assessment of local need, and to commission the services that best suit their population, including decisions about online, face to face or postal testing services. We have set up the national HIV and syphilis self-sampling framework to assist local authority commissioners with providing online testing to their residents.

The Government is committed to improving the sexual health of the nation, including access to, and quality of, sexual health services for the whole population. Public health services commissioned by local authorities in England continue to be funded through a ring-fenced Public Health Grant. In 2024/25, the total Public Health Grant to local authorities has been confirmed at £3.603 billion, through which sexual health services are funded. Local authorities are best placed to commission sexual health services to meet the needs of their local population.

We will work with local government and other key partners to prevent ill health, improve the wider determinants of health, reduce the inequalities that drive poor health, and agree on the most effective interventions to achieve our shared ambitions.

NHS workforce statistics show that in November 2023, there were 243 full time equivalent (FTE) consultants working in the specialty of genito-urinary medicine (GUM) in NHS trusts and other core organisations in England, and 133 FTE consultants working in the specialty of community sexual and reproductive health in NHS trusts and other core organisations in England.

NHS England is responsible for providing HIV care and in March 2024 published the NHS England national service specification for adult specialised services for people living with HIV. Specialised adult inpatient and outpatient HIV services aim to provide specialist assessment and ongoing management of HIV, and associated conditions, to support individuals to stay well, remain engaged in care, and to reduce onward transmission. The services will ensure that outcomes, wellbeing, and quality of life are maximised, that they are culturally competent, in recognition of the disproportionate number of people from diverse backgrounds who access HIV care, and that people are central to decisions about the management of their health and social care.

The Department is consulting with NHS England to reform the funding of specialist training in genito-urinary and HIV care, to increase the ability of specialists to train and then practice in areas of greatest need. We are committed to achieving no new HIV transmissions within England by 2030. As part of the plan, we are investing an additional £20 million for new research, which will involve an expansion and evaluation of bloodborne virus opt-out testing in 47 additional emergency departments in areas of England with high HIV prevalence. This is expected to deliver approximately 1.5 million more HIV tests to help us get people with the virus into care. The Department is also allocating over £3.5 million to deliver a National HIV Prevention Programme between 2021 and 2024 to raise awareness of HIV, sexually transmitted infection (STI) testing, and prevention strategies, targeting populations most at risk of HIV, including young people.

We continue to support the delivery of local sexual health services, providing guidance and data through the UK Health Security Agency and the Department. In March 2023 we published the Integrated Sexual Health Service Specification to support local authorities in comprehensive commissioning of services, and providing advice and guidance on managing STIs outbreaks.

Patient confidentiality is of vital importance to retain patients’ trust in sexual health services, and to encourage access to advice, testing, diagnosis, and treatment of sexually transmitted infections (STIs).

A public consultation seeking views on proposals to amend the Health Protection (Notification) Regulations 2010 was held between 12 July and 15 November 2023. This included the proposal to add specific STIs to schedule 2 of the regulations to strengthen surveillance. The consultation asked for views on the consequences of this change, including whether it could negatively impact public trust in the confidentiality of sexual health services and data and risk creating a barrier to accessing sexual services.

The Department and the UK Health Security Agency are considering the responses to the consultation and are grateful for stakeholders’ continued engagement on this topic.